Frontiers in oncology · 2026
Influencing factors and model predictive analysis of the efficacy of adjuvant ¹³¹I therapy after DTC surgery.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Honghong, Zheng Mingming, Su Qian
Аннотация
OBJECTIVE: To explore influencing factors and construct predictive models for the efficacy of postoperative adjuvant ¹³¹I therapy in patients with differentiated thyroid cancer (DTC).
METHODS: A total of 376 DTC patients who underwent total thyroidectomy and received initial adjuvant ¹³¹I therapy at a fixed activity of 100 mCi were retrospectively enrolled. All patients were divided into excellent response (ER) and non-excellent response (nER) groups according to the 2025 ATA evaluation criteria at the 6-month follow-up. Relevant statistical methods and multivariate binary logistic regression were adopted to screen independent influencing factors. ROC curve analysis, support vector machine (SVM) and random forest (RF) were applied to establish predictive models.
RESULTS: The incidence of nER was 48.40%. BMI, number of metastatic lymph nodes (LNM), stimulated thyroglobulin (s-Tg), BRAF mutation (BRAF) and mean residual ¹³¹I uptake count (C-mean) were independent risk factors (OR = 1.112, 1.061, 1.198, 3.041, 1.103, respectively), while maximum residual ¹³¹I uptake count (C-max) was an independent protective factor (OR = 0.995). The AUC of logistic regression model was 86.30%, and optimal cut-off values were determined as follows: BMI 29.345 kg/m², LNM 9.5 nodes, s-Tg 3.3 ng/ml, C-max 18.5 counts, and C-mean 38 counts. The AUC of SVM model was 86.33%, and the RF model showed the optimal predictive performance with an AUC of 90.77%. S-Tg, LNM and BMI were the top three important predictors. Patients with concurrent high s-Tg, multiple metastatic lymph nodes and elevated BMI had a 100% risk of nER.
CONCLUSION: A considerable proportion of DTC patients fail to achieve ER after 100 mCi adjuvant ¹³¹I therapy. BMI, LNM, s-Tg, BRAF and C-mean are independent risk factors for nER, while C-max are independent protective factors against nER. The RF model possesses excellent predictive ability for adjuvant ¹³¹I treatment response. The coexistence of s-Tg ≥ 3.3 ng/ml, LNM ≥ 9.5 nodes, and BMI ≥ 29.345 kg/m² indicates an extremely high risk of nER, which offers evidence-based support for the judicious escalation of ¹³¹I activity in selected patients undergoing adjuvant therapy.
METHODS: A total of 376 DTC patients who underwent total thyroidectomy and received initial adjuvant ¹³¹I therapy at a fixed activity of 100 mCi were retrospectively enrolled. All patients were divided into excellent response (ER) and non-excellent response (nER) groups according to the 2025 ATA evaluation criteria at the 6-month follow-up. Relevant statistical methods and multivariate binary logistic regression were adopted to screen independent influencing factors. ROC curve analysis, support vector machine (SVM) and random forest (RF) were applied to establish predictive models.
RESULTS: The incidence of nER was 48.40%. BMI, number of metastatic lymph nodes (LNM), stimulated thyroglobulin (s-Tg), BRAF mutation (BRAF) and mean residual ¹³¹I uptake count (C-mean) were independent risk factors (OR = 1.112, 1.061, 1.198, 3.041, 1.103, respectively), while maximum residual ¹³¹I uptake count (C-max) was an independent protective factor (OR = 0.995). The AUC of logistic regression model was 86.30%, and optimal cut-off values were determined as follows: BMI 29.345 kg/m², LNM 9.5 nodes, s-Tg 3.3 ng/ml, C-max 18.5 counts, and C-mean 38 counts. The AUC of SVM model was 86.33%, and the RF model showed the optimal predictive performance with an AUC of 90.77%. S-Tg, LNM and BMI were the top three important predictors. Patients with concurrent high s-Tg, multiple metastatic lymph nodes and elevated BMI had a 100% risk of nER.
CONCLUSION: A considerable proportion of DTC patients fail to achieve ER after 100 mCi adjuvant ¹³¹I therapy. BMI, LNM, s-Tg, BRAF and C-mean are independent risk factors for nER, while C-max are independent protective factors against nER. The RF model possesses excellent predictive ability for adjuvant ¹³¹I treatment response. The coexistence of s-Tg ≥ 3.3 ng/ml, LNM ≥ 9.5 nodes, and BMI ≥ 29.345 kg/m² indicates an extremely high risk of nER, which offers evidence-based support for the judicious escalation of ¹³¹I activity in selected patients undergoing adjuvant therapy.